Candesartan
- Atc Codes:C09CA06
- CAS Codes:139481-59-7#145040-37-5
- PHARMGKB ID:139481-59-7#145040-37-5
Table of contents
- Brand Names
- Drug Combinations
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Toxicological Effects
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Substrate of
- Inhibits
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Atacand, Blopress, Candesartan; Belgium: Atacand; Cyprus: Atacand; Czech Republic: Atacand; Denmark: Amias, Atacand, Ratacand; Estonia: Atacand, Prescanden; Finland: Atacand; France: Atacand, Kenzen; Germany: Amias, Atacand, Blopress, Ratacand; Greece: Atacand; Hungary: Atacand; Ireland: Atacand, Catasart, Blopress; Italy: Blopress, Ratacand; Latvia: Atacand, Prescaden; Lithuania: Atacand; Luxembourg: Atacand; Malta: Atacand; Netherlands: Amias, Atacand, Blopress, Candesartan, Ratacand; Poland: Atacand, Blopress; Portugal: Atacand, Blopress, Candesartan; Romania: Atacand; Slovakia: Atacand, Candesartan; Slovenia: Atacand, Candea; Spain: Atacand, Blopress, Parapres; Sweden: Amias, Atacand, Blopress, Kenzen, Racanda, Ratacand; UK: Amias.
North America
Canada: Atacand; USA: Atacand.
Latin America
Argentina: Atacand, Dacten, Tiadyl; Mexico: Atacand, Blopress.
Asia
Japan: Blopress.
Drug combinations
Candesartan and Hydrochlorothiazide
Chemistry
Candesartan: C~24~H~20~N~6~O~3~. Mw: 440.45. (1) 1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-[[2′-(1H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-; (2) 2-Ethoxy-1-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]-7-benzimidazolecarboxylic acid. CAS-139481-59-7 (1997).
Candesartan Cilexetil: C~33~H~34~N~6~O~6~. Mw: 610.66. (±)-1-Hydroxyethyl 2-ethoxy-1-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]-7-benzimidazolecarboxylate, cyclohexyl carbonate (ester). CAS-145040-37-5 (1997).
Pharmacologic Category
Angiotensin II Receptor Antagonists. (ATC-Code: C09CA06).
Mechanism of action
Candesartan is an angiotensin receptor antagonist, blocking vasoconstriction and the aldosterone-secreting effects (reabsorption of sodium and water) of angiotensin II.
Therapeutic use
Essential hypertension. Heart failure.
Pregnancy and lactiation implications
Based on human data, drugs that act on the angiotensin system can cause injury and death to the developing fetus when used in the second and third trimesters. ACE inhibitors may also increase the risk of major congenital malformations when administered during the first trimester of pregnancy. Contraindicated during lactation.
Unlabeled use
Diabetic nephropathy.
Contraindications
Hypersensitivity to candesartan or any component of the formulation. Severe hepatic impairment and/or cholestasis. Pregnancy. Breast-feeding.
Warnings and precautions
Hyperkalemia might occur (risk factors: renal dysfunction, diabetes mellitus, concomitant use of potassium-sparing diuretics, potassium supplements and/or potassium-containing salts). May be associated with deterioration of renal function and/or increases in serum creatinine, resulting in oliguria, acute renal failure, and progressive azotemia. Use with caution in unstented unilateral/bilateral renal artery stenosis (if unstented bilateral renal artery stenosis is present, use is generally avoided unless possible benefits outweigh risks). Use with caution in significant aortic/mitral stenosis. Use with caution when initiating in heart failure. Hypotension may occur during major surgery and anesthesia. Avoid use or use smaller dose in patients who are volume-depleted. Use with caution in moderate hepatic impairment (contraindicated in severe hepatic impairment and/or cholestasis). Concurrent therapy with ACE inhibitor may be rational in selected patients.